Newsroom

HDL Therapeutics Registration Trial of PDS-2 System in Homozygous Familial Hypercholesterolemia Selected as a 2019 Best of American Heart Association Specialty Conference Presentation, Nov 17 2019

HDL Therapeutics Announces Positive Data From Registration Trial of PDS-2™ System in Homozygous Familial Hypercholesterolemia: May 15 2019

Coronary Atheroma Regression from Serial Infusions of Autologous Selectively Delipidated Preβ-HDL-enriched Plasma on Coronary Atheroma in Patients With Homozygous Familial Hypercholesterolemia in the HALO-FH Trial.  
American Heart Association’s Vascular Discovery: From Genes to Medicine Scientific Sessions May 15 2019

A First in Man, Randomized, Placebo Controlled Study to Evaluate the Safety and Feasibility of Autologous Delipidated High Density Lipoprotein Plasma Infusions in Patients With Acute Coronary Syndrome.
Journal of The American College of Cardiology. 15:55:2727-2735. 2010.  Waksman, Brewer, et al.

Selective Delipidation of Plasma HDL Enhances Reverse Cholesterol Transport In Vivo.
Journal of Lipid Research. 50:894-907.2009.  Sacks, Brewer, et al.